Wolff V, Laurer V, Rouyer O, Sellel F, Meyer N, Raul JS, et al
So far, clinical trial data for elamipretide and bardoxolone underscore the viability of mechanism-driven therapies in treating OSrelated diseases ( Evidence about the role of mtROS has led to the development of MATs for therapeutic intervention in several diseases, including HTN -Figure 2 (Pool et al., 2021), whereas MitoTEMPO can scavenge mtROS, reduce oxidative damage to mitochondria, restore mitochondrial function, and help maintain normal cellular function ( 5.3 NADPH oxidases (NOXs) NOXs are the only known enzymes specifically responsible for generating ROS (Ogrunc et al., 2014)
Current treatment options are limited, underscoring that we need novel therapeutic approaches
-Apply to clean and dry skin on body only
1 comment Excellent and well-explained guide
& Mamitsuka, H